Create your own free news widgets.

LOS ANGELES (Reuters) - A U.S. appeals court on Monday reinstated an Alaska lawsuit against Altria Group Inc's Philip Morris USA by the survivor of a deceased smoker, saying her state product liability claims were not preempted by federal law and should have been tried in state court.

Journal of Natural Products, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Journal of Natural Products)

A Virginia company plans to ask the U.S. Food and Drug Administration (FDA) for permission to market its smokeless-tobacco products as 'modified risk.'

LOS ANGELES (Reuters) - A U.S. appeals court on Monday reinstated an Alaska lawsuit against Altria Group Inc's Philip Morris USA by the survivor of a deceased smoker, saying her state product liability claims were not preempted by federal law and should have been tried in state court.

New technology created more ways we can look foolish while trying to look good.

WINNIPEG, MANITOBA--(Marketwire - Sept. 28, 2009) - Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB(R) Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB(R) wound gel is considered non-cytotoxic and non-irritant. The other FDA-recommended biocompatibility tests (sensitization, genotoxicity and sub-chronic toxicity) are currently in progress.

WINNIPEG, MANITOBA--(Marketwire - Sept. 28, 2009) - Kane Biotech Inc. (TSX VENTURE:KNE) (the 'Company'), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms announces that the exercise period of the Company's early exercise warrant incentive program (the 'Program') has ended. The Program was previously announced in the Company's press release dated August 6, 2009. Existing holders of certain common share purchase warrants of the Company (the 'Warrants') exercised an aggregate of 2,088,500 Warrants at a price of $0.12 per Warrant for aggregate gross proceeds of $250,620. Existing Warrant holders who exercised their Warrants pursuant to the Program shall receive one common share of the Company (a 'Common Share') and one-half of one Common Share purchase warrant (an 'Incentive Warrant') for each Warrant exercised. Each whole Incentive Warrant will have a term

Thommen Medical, a leading Swiss company in the area of the oral implantology, will officially launch the latest products in the evolution of implant surface technology, APLIQUIQ and INICELL, at the 2009 AAOMS Meeting in Toronto, Canada. APLIQUIQ and INICELL-The Innovation is in the Conditioning The introduction of APLIQUIQ and INICELL brings about a new era in state of the art implant dentistry. For the first time, the power is in the hands of the clinician.

Q: On June 22, 2009, President Obama signed the Family smoking Prevention and Tobacco Control Act, which gives FDA the authority to regulate tobacco products. What are your key goals for this legislation? A: Our objective is to use the best available science to develop and put into action effective public health strategies to reduce the enormous toll of illness and death caused by tobacco products. According to the Centers for Disease Control and Prevention, tobacco use causes more than 400,000 deaths each year in the United States-about 1 out of every 5 deaths. On average, adults who smoke cigarettes die 14 years earlier than nonsmokers. And more than 8.5 million Americans have chronic illnesses related to smoking. Despite those facts, 1 in 4 high school students report current tobacco use. About 3,600 kids start smoking and 1,100 kids become regular smokers every day. Our priorities are to * prevent youth from using tobacco; * help adults who use tobacco to quit; * provide accu

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.